On September 4, UBTECH ROBOTICS rose 5.18% in regular trading, trading at 83.2 HKD/share, with turnover of 3.32 billion HKD.
On the news front, the company's ultra-bionic humanoid robot U1 was awarded the Asia-Pacific Medical Innovation Prize, with the first batch of products scheduled to begin delivery on September 16. This event compounds the strong H1 results disclosed on August 28, which showed total revenue of approximately 1.269 billion yuan, up 104.2% year-over-year. Gross profit surged 160.9% to 567 million yuan, with gross margin rising 9.7 percentage points to 44.7%. Net losses narrowed 23.0% to 339 million yuan. Notably, full-size embodied intelligent humanoid robot revenue reached 590 million yuan, soaring 1,445.0% year-over-year and now accounting for 46.5% of total revenue, becoming the company's largest revenue contributor. Total humanoid robot sales reached 16,123 units, up 268.3%. The company has also indicated that Q4 profitability is within reach and plans full-year R&D spending of 700 million yuan.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)